Table 1

Imatinib-naive and imatinib-treated CML-CP–like mice harbor leukemia clones expressing imatinib-resistant BCR-ABL1 kinase mutations

Mice*AssaySensitivityDetection†Mutations
Untreated D-HPLC 10−2 to 10−3 (wt:mut mRNA) 0/7 — 
Imatinib 0/5 — 
Untreated ASO-PCR 10−3 (wt:mut mRNA); 10−3 (cells) 1/7 E255K, T315I 
Imatinib 1/5 T315I 
Untreated Resistant colonies + sequencing 10−6 cells 5/7 E255K, T315I, H396P 
Mice*AssaySensitivityDetection†Mutations
Untreated D-HPLC 10−2 to 10−3 (wt:mut mRNA) 0/7 — 
Imatinib 0/5 — 
Untreated ASO-PCR 10−3 (wt:mut mRNA); 10−3 (cells) 1/7 E255K, T315I 
Imatinib 1/5 T315I 
Untreated Resistant colonies + sequencing 10−6 cells 5/7 E255K, T315I, H396P 
*

Leukemic mice were untreated or treated with imatinib as described in “Methods.”

†

Number of mice with mutations/total number of mice analyzed.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal